1Garber A, Henry R, Ramer R, et al. Liraglufide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono): a randomised, 52-week, phase m, double- blind, parallel-treatment trial[J]. Lancet, 2009, 373(9662): 473-481.
2Garber A, Henry RR, Ramer R, et al. Liraglufide, a once-daily human glucagon- like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monothempy compared with glimepiride in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2011, 13(4): 348-356.
3Mane M, Shaw J, Brandle M, et al. Liralutide a once-daily htanan GLP- 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J]. Diabet Mad, 2009, 26(3): 268- 278.
4Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD(liraglutide effect and action in diabetes)-2 study[l]. Diabetes Care, 2009, 32(1 ): 84-90.
5Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year resdts from the LEAD-2 study[J]. Diabetes Obes Metab, 2013, 15(3): 204-212.
6Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic eonlrol as glimepiride(both in combination with mefformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control Irial(*)[J]. Diabetes Obes Metab, 2011, 13(1): 81-88.
7Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliplin for patients with type 2 diabetes who did not have adequate glyeaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial[J]. Lancet, 2010, 375(9724): 1447-1456.
8Prafley R, Nauck M, Bailey T, et al. One year of liraglutide trealment offers sustained and more effective glycaemie control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial[J]. Int J Clin Pratt, 2011, 65(4): 397-407.
9Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met+TZD)[J]. Diabetes Care, 2009, 32(7): 1224-1230.
10Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus(LEAD-5 met+SU): a randomised controlled trial[J]. Diabetologia, 2009, 52(10): 2046-2055.
二级参考文献32
1Gallwitz B.GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.Handb Exp Pharmacol,2011,203:53-74.
2Jahn E,Sausele T.Liraglutide:a human GLP-1 analogue for the treatment of diabetes mellitus type 2.Med Monatsschr Pharm,2009,32:402-407.
3Rossi MC,Nicolucci A.Liraglutide in type 2 diabetes:from pharmacological development to clinical practice.Acta Biomed,2009,80:93-101.
5Schmidt WE.Early clinical studies with liraglutide.Int J Clin Pract Suppl,2010,64:12-20.
6Marre M,Shaw J,Brandle M,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).Diabet Med,2009,26:268-278.
7Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD (liraglutide effect and action in diabetes)-2 study.Diabetes Care,2009,32:84-90.
8Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono):a randomised,52-week,phase III,double-blind,parallel-treatment trial.Lancet,2009,373:473-481.
9Zinman B,Gerich J,Buse JB,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).Diabetes Care,2009,32:1224-1230.
10Russell-Jones D,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU):a randomised controlled trial.Diabetologia,2009,52:2046-2055.
